Daiichi Sankyo's Q1 2026 Revenue Surges on Oncology Growth Despite Profit Dip — Daiichi Sankyo Company, Limited

Event summary

Q1 FY2026 global revenue up 21.1% YoY to ¥574.7B, driven by oncology products Enhertu and Datroway.
Operating profit fell 12.0% YoY to ¥85.1B due to EU restructuring costs.
Three new U.S. approvals for Enhertu and Datroway in May 2026 expanded breast cancer indications.
Full-year guidance raised: revenue now projected at ¥2.34T (up from ¥2.28T) and operating profit at ¥320B (up from ¥315B).
Q4 FY2025 operating profit revised upward by ¥28.9B due to SG&A expense correction.

The big picture

Daiichi Sankyo's strong Q1 performance underscores the strategic shift toward oncology, with Enhertu and Datroway driving growth. The company's ability to secure multiple regulatory approvals in rapid succession positions it competitively against larger biopharma players. However, restructuring costs highlight the challenges of transforming legacy business units while investing in high-growth areas.

What we're watching

Pipeline Execution: Whether Daiichi Sankyo can sustain its rapid approval pace for Enhertu and Datroway across multiple cancer types.
Restructuring Impact: How EU Specialty Business restructuring costs will affect full-year profitability despite revenue growth.
Strategic Focus: The pace at which Daiichi Sankyo transitions from a diversified healthcare company to an oncology-focused business through the Suntory deal.